RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hemogenyx Pharmaceuticals Stock

Hemogenyx Pharmaceuticals P/S 2024

Hemogenyx Pharmaceuticals P/S

0

Ticker

HEMO.L

ISIN

GB00BYX3WZ24

WKN

A143YN

As of Nov 18, 2024, Hemogenyx Pharmaceuticals's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The Hemogenyx Pharmaceuticals P/S history

Hemogenyx Pharmaceuticals Aktienanalyse

What does Hemogenyx Pharmaceuticals do?

Hemogenyx Pharmaceuticals PLC is a biotechnology company based in London that develops therapies based on human blood stem cells. The company focuses on developing therapies in three areas: CAR-T cell therapy, blood stem cell therapy, and cell therapy to support immune defense. Hemogenyx has already developed several products and has partnerships with institutions such as the University of Edinburgh. The company went public in 2018 and has invested heavily in the development of new therapies. Hemogenyx Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Hemogenyx Pharmaceuticals's P/S Ratio

Hemogenyx Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Hemogenyx Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Hemogenyx Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Hemogenyx Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Hemogenyx Pharmaceuticals stock

What is the price-to-earnings ratio of Hemogenyx Pharmaceuticals?

The price-earnings ratio of Hemogenyx Pharmaceuticals is currently 0.

How has the price-earnings ratio of Hemogenyx Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Hemogenyx Pharmaceuticals has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Hemogenyx Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Hemogenyx Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Hemogenyx Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Hemogenyx Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Hemogenyx Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Hemogenyx Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Hemogenyx Pharmaceuticals?

Some factors that influence the price-earnings ratio of Hemogenyx Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Hemogenyx Pharmaceuticals pay?

Over the past 12 months, Hemogenyx Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hemogenyx Pharmaceuticals is expected to pay a dividend of 0 GBP.

What is the dividend yield of Hemogenyx Pharmaceuticals?

The current dividend yield of Hemogenyx Pharmaceuticals is .

When does Hemogenyx Pharmaceuticals pay dividends?

Hemogenyx Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Hemogenyx Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hemogenyx Pharmaceuticals located?

Hemogenyx Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hemogenyx Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hemogenyx Pharmaceuticals from 11/18/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 11/18/2024.

When did Hemogenyx Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/18/2024.

What was the dividend of Hemogenyx Pharmaceuticals in the year 2023?

In the year 2023, Hemogenyx Pharmaceuticals distributed 0 GBP as dividends.

In which currency does Hemogenyx Pharmaceuticals pay out the dividend?

The dividends of Hemogenyx Pharmaceuticals are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hemogenyx Pharmaceuticals

Our stock analysis for Hemogenyx Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hemogenyx Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.